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mented as causes of angina in patients who had normal 
coronary arteriograms.’ 
Unfortunately, coronary vasodilatory flow reserve before 
or during this study was not measured. One would antici- 
pate significant abnormality of the vasodilatory response. 
Syndrome X, a constellation of findings of chest pain, my- 
ocardial ischemia, ECG abnormalities, and normal coro- 
nary arteries, is the most likely diagnosis in this particular 
patient. This case emphasizes that cardiologists who per- 
form ergonovine tests should be aware that ECG alter- 
ations, particularly those of an atypical response, can occur 
in a patient with normal coronary arteries. Prolonged 
ischemia may be difficult to manage, and, although absent 
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Effect of verapamil on infranodal 
conduction in patients with baseline 
His-Purkinje conduction delay 
Shimon Rosenheck, MD, Joao Sousa, MD, 
Hugh Calkins, MD, Alan H. Kadish, MD, and 
Fred Morady, MD. Ann Arbor, Mich. 
Several experimental and clinical studies have demon- 
strated that verapamil does not depress infranodal con- 
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duction when baseline conduction is normal.‘, 2 The ab- 
sence of a depressive effect of a calcium channel blocking 
agent on infranodal conduction is consistent with the fact 
that depolarization of normal His-Purkinje fibers depends 
on sodium channels.3 However, in damaged His-Purkinje 
fibers, as in fibers suspended in sodium-free solution, the 
action potential has a lower resting potential, slower depo- 
larization velocity, and a longer duration, suggesting the 
use of slow calcium channels instead of fast sodium 
channels4 Therefore it is possible that verapamil might 
depress conduction in the His-Purkinje system when base- 
line conduction is abnormal. Although a recent study5 
demonstrated that verapamil has no effect on rate-depen- 
dent bundle branch block, no studies have investigated the 
direct effect of verapamil on the diseased His-Purkinje 
system. Therefore the purpose of this study was to evalu- 
ate the effect of verapamil on infranodal conduction in pa- 
tients with baseline conduction delay in the His-Purkinje 
system. 
Five patients with prolonged infranodal conduction were 
studied. There were four men and one woman, and their 
mean age was 69 2 8 years (&standard deviation). Four 
patients had no structural heart disease and one had cor- 
onary artery disease; their mean left ventricular ejection 
fraction was 0.52 +- 0.13. Two patients had a left bundle 
branch block, two had a right bundle branch block and left 
anterior hemiblock, and one had a right bundle branch 
block and left posterior hemiblock. The baseline HV inter- 
val was 70 to 170 msec (mean 98 ? 42 msec). After 
informed consent was obtained, each patient underwent an 
electrophysiology test for evaluation of syncope or ventric- 
ular tachycardia. Three quadripolar electrode catheters 
were positioned in the right atrium, the right ventricular 
apex, and across the tricuspid valve to record the His bun- 
dle electrogram. Leads I, III, Vr and the intracardiac elec- 
trograms were recorded with a Siemens-Elema Mingograf 
7 recorder (Siemens Elema AB, Solna, Sweden) at a paper 
speed of 100 mm/set. The AH and HV intervals and the 
duration of the His bundle depolarization were measured 
at atria1 pacing cycle lengths of 700,600, and 500 msec. The 
atrioventricular (AV) block cycle length was determined by 
incremental atria1 pacing in steps of 10 msec. At each pac- 
ing cycle length, measurements were made from five con- 
secutive paced beats after at least 20 seconds of pacing, and 
the means of the measurements were used for analysis. 
Measurements were made in the baseline state and 3 min- 
utes after the infusion of consecutive doses of 10,5, and 5 
mg of verapamil. These doses of verapamil were infused 
over 3 to 5 minutes and were separated by 5-minute inter- 
vals. Mixed model analysis of variance was used for statis- 
tical analysis. 
The effects of verapamil are described in Table I. The 10, 
15, and 20 mg cumulative dosages of verapamil signifi- 
cantly prolonged the AV node block cycle length (p < 0.01) 
and AH interval (p < 0.05), but had no effect on the HV 
interval or His duration. A decrease in the atria1 pacing cy- 
cle length resulted in a significant increase in the AH 
interval (p < 0.01) and had no effect on the HV interval and 
His duration. Three patients had infranodal block in the 
baseline state. After verapamil infusion, these three pa- 
tients either developed AV nodal Wenckebach block at a 
June 1991 
18 10 Brief Communications American Heart Journal 
Table I. The effect of 10, 15, and 20 mg of verapamil injected intravenously on the sinus cycle length, AH and HV 
intervals, His deflection duration, and AV nodal block cycle lengths (in milliseconds) 
Verapamil 








A7’N BCL I 
AVN BCL II 
786 k 101 
112 t 31 
123 k 26 
98 k 42 
87 It 12 
19 + 2 
21 + 6 
464 _t 136 
402 ‘- 116 
782 I 88 
130 + 55* 
136 t 46* 
a7 + 21 
103 k 22 
23 + 6 
25 k 6 
500 i a9* 
436 -t 94 
772 t 65 
140 i 70* 
149 i 52* 
88 i 13 
108 i 43 
23 + 6 
23 I~I 5 
530 t 110* 
454 rt; 95 
792 t 60 
125 z 63* 
153 i 46* 
a5 i- 10 
107 i- 31 
23 ?I 5 
25 +- 6 
530 t 79* 
468 i- 68 
PCL, Pacing cycle length; XL, sinus cycle length; AVN BCL I, AV node Wenkebach block cycle length; AVN BCL II, AV node 2:l block cycle length. 
*p < 0.05, compared with baseline. 
cycle length longer than the infranodal block cycle length, 
or had no change in the pacing cycle length at which the 
infranodal block occurred. 
The present study demonstrates that verapamil has no 
effect on the severely impaired His-Purkinje system in hu- 
man subjects. In contrast to these results, experimental 
studies have demonstrate a depressant effect of verapamil 
on conduction in the damaged His-Purkinje system.6 
However, these experimental studies were performed using 
in vitro preparations that may not have accurately simu- 
lated in vivo conditions. For example, a Na+-free tissue 
bath was used.6 The present study demonstrates that the 
use of verapamil in patients with a prolonged HV interval 
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Fatal verapamil toxicity and hypokalemia 
Ricci A. Minella, MD, and Douglas S. Schulman, MD 
Pittsburgh, Pa. 
Verapamil is a commonly prescribed calcium channel 
blocking drug. The predominant mechanism of its actions 
and side effects is mediated through slow calcium channel 
blockade. Although not common, severe verapamil over- 
dose has been reported.’ We report a case of fatal verapamil 
overdose that demonstrates the salient features of acute 
verapamil toxicity. 
The patient was a previously healthy 33-year-old white 
man who presented 20 minutes after ingesting 52 80 mg 
verapamil tablets (4.16 gm) in a suicide attempt. The med- 
icine was prescribed for a family member. Initially, he was 
alert with a pulse of 103 beats/min and a blood pressure of 
110/70 mm Hg. Initial laboratory values of note seen within 
20 minutes of presentation included a potassium level of 2.8 
mEq/dl, a glucose level of 252 mg/dl, a calcium level of 9.9 
mEq/dl, a magnesium level of 1.4 mEq/dl, a verapamil level 
of 2060 rig/ml (50 to 200 rig/ml therapeutic), and a norver- 
apamil level of 523 rig/ml (50 to 200 rig/ml). He was treated 
with gastric lavage, syrup of ipecac, and activated charcoal. 
His heart rate and blood pressure began to decrease and he 
developed first-degree atrioventricular (AV) block (Fig. 1). 
Within 25 minutes, his blood pressure had decreased to 
97/50 mm Hg and his heart rate had slowed to 61 beats/min. 
The patient was given 3 ampules of (1 gm/amp) calcium 
chloride, 1 mg atropine, 0.4 mg naloxone hydrochloride and 
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